Stefan Wohlfeil
Direttore/Membro del Consiglio presso Actimed Therapeutics Ltd.
Posizioni attive di Stefan Wohlfeil
Società | Posizione | Inizio | Fine |
---|---|---|---|
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Direttore/Membro del Consiglio | 01/05/2019 | - |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Stefan Wohlfeil
Precedenti posizioni note di Stefan Wohlfeil
Società | Posizione | Inizio | Fine |
---|---|---|---|
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Direttore Tecnico/Scientifico/R&S | 01/01/2013 | 01/01/2019 |
TRIN Pharma GmbH
TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | Presidente | 03/12/2009 | 23/05/2011 |
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Direttore/Membro del Consiglio | 01/03/2019 | - |
OM Pharma SA
OM Pharma SA Pharmaceuticals: MajorHealth Technology OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland. | Corporate Officer/Principal | 01/01/2012 | - |
VIFOR PHARMA | Direttore Tecnico/Scientifico/R&S | 01/01/2013 | - |
Bayer Pharma Chemicals Co. | Corporate Officer/Principal | - | - |
Atani Ltd.
Atani Ltd. Pharmaceuticals: GenericHealth Technology Atani Ltd. manufactures and markets drugs. The firm's drugs are used for the treatment of cancer. The company was founded by Stefan Wohlfeil and is headquartered in Tokyo, Japan | Fondatore | 05/08/2009 | - |
Presidente | - | - |
Statistiche
Distribuzione geografica
Svizzera | 7 |
India | 2 |
Giappone | 2 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
President | 2 |
Settori
Health Technology | 6 |
Health Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 9 |
---|---|
Vifor Pharma AG
Vifor Pharma AG Pharmaceuticals: MajorHealth Technology Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland. | Health Technology |
Bayer Pharma Chemicals Co. | |
TRIN Pharma GmbH
TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | Health Services |
Atani Ltd.
Atani Ltd. Pharmaceuticals: GenericHealth Technology Atani Ltd. manufactures and markets drugs. The firm's drugs are used for the treatment of cancer. The company was founded by Stefan Wohlfeil and is headquartered in Tokyo, Japan | Health Technology |
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Health Technology |
OM Pharma SA
OM Pharma SA Pharmaceuticals: MajorHealth Technology OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland. | Health Technology |
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Health Services |
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Health Technology |
- Borsa valori
- Insiders
- Stefan Wohlfeil
- Esperienza